Molter G, Larsen R, Peters U, Bauch U, Sefrin R
Department of Anaesthesiology and Intensive Care, University of Saarland, Homburg/Saar, Germany.
Br J Anaesth. 1993 Apr;70(4):428-33. doi: 10.1093/bja/70.4.428.
We have investigated the circulatory effects of halothane and isoflurane in the presence of the phosphodiesterase inhibitor, enoximone, in 20 patients, ASA class III, aged 40-70 yr, undergoing coronary artery bypass grafting. After induction of anaesthesia (midazolam, fentanyl, etomidate and pancuronium) all patients received enoximone 0.5 mg kg-1, followed, 10 min later, by either halothane 1 MAC (group I; n = 10) or isoflurane 1 MAC (group II; n = 10). Haemodynamic variables were measured and blood samples (arterial and mixed venous) were obtained before (control, t0), 5 (t1) and 10 (t2) min after the injection of enoximone and immediately (t3) and 5 (t4) min after steady state conditions with halothane or isoflurane, as verified by the end-expiratory concentration. Heart rate, mean arterial pressure (MAP), mean pulmonary artery pressure, pulmonary capillary wedge pressure and right atrial pressure were recorded. Cardiac (CI) and stroke volume indices, systemic (SVR) and pulmonary vascular resistance, oxygen availability (QO2), oxygen consumption and oxygen extraction rate were calculated using standard formulae. MAP decreased significantly in both groups after bolus injection of enoximone (group I: 11%; group II: 7%). Under steady state conditions with the volatile anaesthetics, a further significant decrease in MAP was observed (group I: 12%; group II: 12%). Enoximone produced a significant increase in CI (group I: 25%; group II: 27% compared with control). After administration of isoflurane, CI remained essentially unchanged, while halothane decreased CI significantly by 20%. In both groups, SVR decreased significantly after administration of enoximone (group I: 26%; group II: 24%).(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了在20例年龄40 - 70岁、ASAⅢ级、行冠状动脉搭桥术的患者中,磷酸二酯酶抑制剂依诺昔酮存在时氟烷和异氟烷对循环系统的影响。麻醉诱导(咪达唑仑、芬太尼、依托咪酯和泮库溴铵)后,所有患者接受0.5mg/kg依诺昔酮,10分钟后,I组(n = 10)给予1MAC氟烷,II组(n = 10)给予1MAC异氟烷。在注射依诺昔酮前(对照,t0)、注射后5分钟(t1)和10分钟(t2)以及在呼气末浓度证实达到氟烷或异氟烷稳态后立即(t3)和5分钟(t4)测量血流动力学变量并采集血样(动脉血和混合静脉血)。记录心率、平均动脉压(MAP)、平均肺动脉压、肺毛细血管楔压和右心房压。使用标准公式计算心排血量(CI)和每搏量指数、体循环(SVR)和肺血管阻力、氧供(QO2)、氧耗和氧摄取率。推注依诺昔酮后两组MAP均显著下降(I组:11%;II组:7%)。在挥发性麻醉药稳态条件下,MAP进一步显著下降(I组:12%;II组:12%)。依诺昔酮使CI显著增加(I组:与对照相比增加25%;II组:增加27%)。给予异氟烷后,CI基本保持不变,而氟烷使CI显著下降20%。两组给予依诺昔酮后SVR均显著下降(I组:26%;II组:24%)。(摘要截短于250字)